在RET融合阳性肺癌中RET抑制剂:过去,现在和未来
Monica F Chen1,2,3, Matteo Repetto2, Clare Wilhelm1,2
1Thoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.
Drugs
|July 12, 2024
概括
RET 抑制剂已推进癌症治疗,选择性氨酸激酶抑制剂 (TKI) 与早期药物相比显示出更好的疗效和安全性. 未来的研究重点是克服依赖RET的癌症中抵抗机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 激活RET融合是各种癌症,特别是肺癌的关键驱动因素.
- 早期的治疗涉及多酶抑制剂,成功程度有限,毒性显著.
- 具有RET融合阳性的肺癌和甲状腺癌一直是RET抑制剂开发的核心.
研究的目的:
- 对RET融合阳性癌症的RET抑制剂的临床发展进行审查.
- 为了比较第一代选择性RET TKI与多酶抑制剂的疗效和安全性.
- 讨论RET抑制剂的演变,包括针对抗性突变的下一代药物.
主要方法:
- 对RET抑制剂的临床试验数据和科学文献的审查.
- 对药物开发时间表和治疗结果的分析.
- 药物选择性,疗效,安全性和耐药性概况的比较.
主要成果:
- 与多酶抑制剂相比,第一代选择性RET氨酸激酶抑制剂 (TKIs) 显示出更高的反应率,持久的疾病控制和更好的安全性.
- 选择性的RET TKIs导致了对肺部,甲状腺和其他RET融合阳性瘤的监管批准.
- 下一代RET TKI的开发是为了解决耐药性突变,但往往具有较低的选择性.
结论:
- 选择性RET TKIs在治疗依赖RET的癌症方面取得了重大进展.
- RET抑制剂的开发已经从广泛作用的药物发展到高度向的治疗方法.
- 未来的药物开发必须平衡对抗耐药性的有效性,以及对目标选择性和安全性的需求.
相关概念视频
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166